Beckman Coulter vs. Sysmex
Our key hematology initiative improved instrument quality and reliability for our customers. The results spoke for themselves in these third-party data scores from MD Buyline, published in late 2019. (See Figure 1.)
DxH 800 and DxH 900 MD Buyline Ratings, as of Q4 2019*
Figure 1. Our DxH hematology platform posted cumulative gains in overall composite score and five other key categories in Q4 2019.
MD Buyline compared our DxH hematology analyzers to competitors in the medical device industry. They obtained feedback by randomly calling users and customers who volunteered to answer their surveys. All of the survey participants were high-volume laboratories with instruments greater than two years old at the time the survey was sent.
Looking for answers when it comes to “Beckman vs. Sysmex”? Consider these highlights from MD Buyline’s findings:
- DxH scores for applications training, service response time and overall score beat Sysmex
- DxH platform system performance score improved by seven points over the previous six quarters
- Beckman Coulter was recognized as the top-performing provider two quarters in a row (third and fourth quarters of 2019)
According to MD Buyline ratings, customer satisfaction with several key facets of the DxH platform is growing.
Now you can bring the strengths of the DxH platform to your laboratory with the benefit of the latest generation hematology technology. The new DxH 900 hematology analyzer offers innovative, laboratory-inspired upgrades such as streamlined quality assurance, twice the walkaway time for reagent placement, a smaller operational footprint and an FDA-cleared sepsis marker. Learn more about the DxH 900 hematology analyzer ›